source
- Bristol Myers reports Phase 2 success for GPRC5D‑directed CAR‑T therapyBristol Myers announced positive Phase 2 results for its GPRC5D‑directed CAR‑T therapy aimed at treating multiple myeloma. The study demonstrated encouraging efficacy signals, adding to the growing…
- Novartis halts CD19 CAR-T trial after three deaths, Bristol Myers also pauses similar programNovartis announced a pause to its CD19-directed CAR-T cell therapy trials after three patients experienced fatal immune reactions. The company said the deaths were linked to a severe cytokine relea…